Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26528362 | 0.93 | MET (0.38) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26530915 | 0.92 | MET (0.36) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26999050 | 0.89 | MET (0.46) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23528415 | 0.88 | MET (0.39) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23528553 | 0.88 | MET (0.43) | METPDE4APDE4BPDE4CPDE4D | |
| Sevasemten SCHEMBL23528413 | 0.87 | MET (0.42) | METMEN1KMT2A | |
| SCHEMBL23528794 | 0.87 | GRIN1 (0.42) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23528288 | 0.86 | GRIN1 (0.45) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23528333 | 0.86 | MET (0.40) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23528290 | 0.85 | MET (0.38) | METPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2021231615-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210188814-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188814-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MET 4319/4885PDE4A 305/4885PDE4B 618/4885 |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | MET 4344/4885PDE4A 227/4885PDE4B 427/4885 |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885PDE4A 369/4885PDE4B 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.